ArticleJCO global oncology2023

Cost Evaluation Analysis of Genetic Testing and Tailored Adjuvant Imatinib in Patients With Resected High-Risk GI Stromal Tumors: The Brazilian Perspective.

Bruna Bianca Lopes David et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.